Literature DB >> 31762401

Prognostic value of IL-34 in colorectal cancer patients.

Takuto Kobayashi1, Muhammad Baghdadi1, Nanumi Han1, Tomoki Murata1, Naoki Hama1, Ryo Otsuka1, Haruka Wada1, Manabu Shiozawa2, Tomoyuki Yokose3, Yohei Miyagi4, Atsushi Takano5,6,7, Yataro Daigo5,6,7, Ken-Ichiro Seino1.   

Abstract

The mortality of colorectal cancer is expected to increase in some countries including the United States, which necessitates the identification of new molecules that help in prognosis assessment and survival improvement. In this brief report, we evaluated the potential of interleukin-34 (IL-34) as a prognostic factor in colorectal cancer. IL-34 was reported for the first time in 2008 as a novel cytokine that controls the biology of the myeloid cell lineage. Accumulating evidence suggests important roles for IL-34 in modifying the tumor microenvironment and enhancing therapeutic resistance of cancer. In this study, we found that IL-34 expression was detectable in various colorectal cancer cell lines in addition to primary cancer tissues from a cohort of Japanese colorectal cancer patients, ranging from high to absent. A Kaplan-Meier analysis showed that high expression of IL-34 correlated with poor survival of colorectal cancer patients. Importantly, in both univariate and multivariate analysis, high IL-34 expression correlated with unfavorable prognosis. A similar relationship between IL-34 expression and the poorer prognosis was also observed in a cohort of colorectal cancer patients registered at The Cancer Genome Atlas. Together, these findings indicate a potential role for IL-34 as a prognostic factor in colorectal cancer.

Entities:  

Keywords:  Colorectal cancer; immunohistochemistry; in silico; interleukin-34; prognosis

Mesh:

Substances:

Year:  2019        PMID: 31762401     DOI: 10.1080/25785826.2019.1691429

Source DB:  PubMed          Journal:  Immunol Med        ISSN: 2578-5826


  7 in total

Review 1.  IL-34, IL-36 and IL-38 in colorectal cancer-key immunoregulators of carcinogenesis.

Authors:  Shisan Bao; Rong Hu; Brett D Hambly
Journal:  Biophys Rev       Date:  2020-07-07

2.  Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.

Authors:  Nabeel Kajihara; Takuto Kobayashi; Ryo Otsuka; Junko Nio-Kobayashi; Tomohiro Oshino; Masato Takahashi; Seiichi Imanishi; Ari Hashimoto; Haruka Wada; Ken-Ichiro Seino
Journal:  Cancer Immunol Immunother       Date:  2022-09-14       Impact factor: 6.630

Review 3.  The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis.

Authors:  Javier Muñoz-Garcia; Denis Cochonneau; Stéphane Télétchéa; Emilie Moranton; Didier Lanoe; Régis Brion; Frédéric Lézot; Marie-Françoise Heymann; Dominique Heymann
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 4.  Cross Talk Between Macrophages and Cancer Cells in the Bone Metastatic Environment.

Authors:  Lena Batoon; Laurie K McCauley
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-03       Impact factor: 5.555

5.  IL-34 in hepatoblastoma cells potentially promote tumor progression via autocrine and paracrine mechanisms.

Authors:  Tomoaki Irie; Daiki Yoshii; Yoshihiro Komohara; Yukio Fujiwara; Masashi Kadohisa; Masaki Honda; Shinya Suzu; Toshiharu Matsuura; Kenichi Kohashi; Yoshinao Oda; Taizo Hibi
Journal:  Cancer Med       Date:  2022-02-08       Impact factor: 4.452

6.  Differential Expression and Prognostic Correlation of Immune Related Factors Between Right and Left Side Colorectal Cancer.

Authors:  Yue Hu; Jie Ding; Chengjiang Wu; Hong Gao; Meiling Ge; Qixiang Shao; Yanhong Liu; Qing Ye
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

Review 7.  Targeting IL-34/MCSF-1R Axis in Colon Cancer.

Authors:  Giovanni Monteleone; Claudia Maresca; Marco Colella; Teresa Pacifico; Daniele Congiu; Edoardo Troncone; Irene Marafini
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.